Q4 2024 HLS Therapeutics Inc Earnings Call Transcript
Key Points
- HLS Therapeutics Inc (HLTRF) achieved significant growth in core products, with Vascepa and Clozaril becoming profitable contributors.
- The company successfully reduced operating expenses by double digits, leading to a 42% increase in adjusted EBITDA, excluding royalty revenues.
- HLS Therapeutics Inc (HLTRF) strengthened its balance sheet by paying down over $20 million in debt and divesting non-core assets.
- The leadership team was bolstered with key appointments, including John Hanna as CFO and Brian Walsh as Chief Commercial Officer.
- The company has full control over Vascepa's commercialization, allowing for strategic allocation of resources and marketing investments.
- 2024 revenue was at the lower end of the guidance range, impacted by foreign exchange fluctuations.
- US Clozaril net sales declined by about 7% from the prior year, with challenges in wholesaler inventory levels.
- The company faces ongoing challenges with payer mix, particularly with prescription growth in the less profitable public channel outpacing the private insurance segment.
- The potential impact of US tariffs and foreign exchange rate fluctuations remain external risks to the business.
- Despite improvements, Vascepa's contribution to adjusted EBITDA was still negative for the full year, indicating room for further profitability enhancements.
Good morning, and welcome to the Q4 and fiscal 2024 financial results conference call for HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations for the introductory remarks.
Good morning, everyone, and thank you for joining us today. With me on today's call Craig Millian, CEO; John Hanna, CFO; and Brian Walsh, Chief Commercial Officer.
Earlier this morning, we issued a news release announcing our financial results for the 3 and 12 months ended December 31, 2024. This news release, along with our MD&A and financial statements, is available on HLS's website and on SEDAR+. Please note that slides accompanying today's call can be viewed via the webcast, a link to which is available in our earnings press release on our website on the Events page.
Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results differ materially from those anticipated.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
